COMMUNITY REGIONAL CANCER CENTER MOBILE DOCUMENTATION SYSTEM v3.2 APRIL 14, 2025 A PATIENT SNAPSHOT L Clarissa McEwen (MRN: SYN180 ( 7 12/28/1961 📥 04/08/2025 - 04/14/2025 III Interventional Radiology/Oncology DIAGNOSIS Liver abscess post-TACE in patient with hepatic metastases from NSCLC CASE SUMMARY • 63F with NSCLC (dx 10/2021) • High PD-L1 (80%) • No driver mutations • Liver mets at diagnosis • On pembrolizumab since 10/10/2021 • Good systemic response but single progressing liver lesion (segment V) • Underwent TACE to isolated progressing lesion on 04/06/2025 • Admitted with post-TACE abscess LABS ON ADMISSION WBC: 18.4 × 10³/µL 1 Neutrophils: 85% 1 Bands: 8% 1 Hgb: 11.2 g/dL U Platelets: 268 × 10³/µL CRP: 124 mg/L 1 Procalcitonin: 3.8 ng/mL 1 ALT: 168 U/L 1 AST: 145 U/L 1 ALP: 210 U/L 1 T.Bili: 1.4 mg/dL 1 INR: 1.2 Blood cultures: Klebsiella pneumoniae ✓ LABS AT DISCHARGE WBC: 8.6 × 10³/µL Neutrophils: 68% Bands: 0% Hgb: 10.8 g/dL U Platelets: 315 × 10³/μL CRP: 22 mg/L 1 ALT: 64 U/L 1 AST: 48 U/L ALP: 142 U/L 1 T.Bili: 0.8 mg/dL INR: 1.1 **III** IMAGING STUDIES CT ABDOMEN (04/08/2025) • 4.8 × 3.9 cm rim-enhancing fluid collection in segment V at TACE site • Gas bubbles within collection • Perilesional edema • Multiple other smaller hypodense lesions throughout liver (stable from prior) CT ABDOMEN (04/13/2025) • Abscess decreased to 3.2 × 2.5 cm • Resolution of gas bubbles • Drainage catheter in good position • No new collections CHEST CT (04/09/2025) • Primary RML tumor stable (1.2 cm) • No lymphadenopathy • No new pulmonary nodules INTERVENTIONS • US-guided percutaneous drainage of abscess (04/08) • Culturedirected antibiotics (meropenem) • Daily catheter check/flush • Catheter removed prior to discharge DISCHARGE MEDICATIONS • Ertapenem 1g IV daily × 10 more days (PICC) • Pembrolizumab resumed on 04/28/2025 • Acetaminophen 650mg q6h PRN pain • Pantoprazole 40mg daily ■ FOLLOW-UP PLAN • ID follow-up 04/21/2025 • Oncology visit 04/28/2025 • PICC line

removal after antibiotics complete • CT abdomen in 4 weeks • Resume pembrolizumab

in 2 weeks if well.

✓ RESPONSE TO THERAPY • Defervescence after 72hrs • Resolution of RUQ pain • Normalization of WBC • Decreasing liver enzymes • 33% decrease in abscess size

RESPONSIBLE PROVIDER Dr. Wilson Oncology/IR 4/14/2025 15:35